Mutated variants of the two PLCγ enzymes, PLCγ1 and PLCγ2, have been linked to specific cancers (including T-cell lymphoma and angiosarcoma), resistance to cancer treatment (e.g. CCL resistance to ibrutinib), complex, dominantly inherited immune disorders (originally designated as PLAID and APLAID) and inflammation as well as with protection in Alzheimer’s and related neurodegenerative diseases; the major, comprehensive discoveries are described in [4–9]. This evidence concerns the gene PLCG1 and cancer.